Cara Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Ronald A. DePinho has filed an amended Schedule 13G, reporting beneficial ownership of 6.7% of TVARDI THERAPEUTICS, INC.'s common stock as of September 30, 2025.
Slate Path Capital LP and David Greenspan have disclosed a 7.5% passive beneficial ownership stake in Tvardi Therapeutics, Inc., holding 704,118 shares of common stock.
Sporos Bioventures LLC has disclosed a significant 8.95% beneficial ownership stake in Tvardi Therapeutics, Inc. common stock.
Samuel D. Tweardy files an amended Schedule 13G, reporting beneficial ownership of 3.4% of TVARDI THERAPEUTICS, INC. common stock.
Ronald A. DePinho has filed a Schedule 13G, disclosing beneficial ownership of 8.3% of TVARDI THERAPEUTICS, INC.'s common stock.
Samuel D. Tweardy has reported a 10.1% beneficial ownership stake in TVARDI THERAPEUTICS, INC., holding 946,974 shares through various trusts.
David J. Tweardy has reported a 7.0% beneficial ownership stake in TVARDI THERAPEUTICS, INC., comprising 652,398 shares of common stock.
Solas Tvardi Sidecar LLC, Solas BioVentures Fund II, LP, and Solas Partners II, LLC have jointly disclosed a passive beneficial ownership of 8.1% in Tvardi Therapeutics, Inc.'s common stock.